Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Colorectal Neoplasms

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 123 articles:
HTML format
Text format



Single Articles


    March 2017
  1. DE LA MARE JA, Jurgens T, Edkins AL
    Extracellular Hsp90 and TGFbeta regulate adhesion, migration and anchorage independent growth in a paired colon cancer cell line model.
    BMC Cancer. 2017;17:202.
    PubMed     Text format     Abstract available


    February 2017
  2. TSUJII Y, Hayashi Y, Maekawa A, Fujinaga T, et al
    Cardiac metastasis from colon cancer effectively treated with 5-fluorouracil, leucovorin, and oxaliplatin (modified FOLFOX6) plus panitumumab: a case report.
    BMC Cancer. 2017;17:152.
    PubMed     Text format     Abstract available


  3. HE Z, Yu L, Luo S, Li M, et al
    miR-296 inhibits the metastasis and epithelial-mesenchymal transition of colorectal cancer by targeting S100A4.
    BMC Cancer. 2017;17:140.
    PubMed     Text format     Abstract available


  4. MA J, Yang QL, Ling Y
    Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.
    BMC Cancer. 2017;17:132.
    PubMed     Text format     Abstract available


  5. RIGTER LS, Spaander MC, Moons LM, Bisseling TM, et al
    Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design.
    BMC Cancer. 2017;17:112.
    PubMed     Text format     Abstract available


  6. CAREY M, Sanson-Fisher R, Macrae F, Cameron E, et al
    Improving adherence to colorectal cancer surveillance guidelines: results of a randomised controlled trial.
    BMC Cancer. 2017;17:106.
    PubMed     Text format     Abstract available


  7. IRELAND MJ, March S, Crawford-Williams F, Cassimatis M, et al
    A systematic review of geographical differences in management and outcomes for colorectal cancer in Australia.
    BMC Cancer. 2017;17:95.
    PubMed     Text format     Abstract available


    January 2017
  8. HENRIKSEN HB, Raeder H, Bohn SK, Paur I, et al
    The Norwegian dietary guidelines and colorectal cancer survival (CRC-NORDIET) study: a food-based multicentre randomized controlled trial.
    BMC Cancer. 2017;17:83.
    PubMed     Text format     Abstract available


  9. VAN ZUTPHEN M, Winkels RM, van Duijnhoven FJ, van Harten-Gerritsen SA, et al
    An increase in physical activity after colorectal cancer surgery is associated with improved recovery of physical functioning: a prospective cohort study.
    BMC Cancer. 2017;17:74.
    PubMed     Text format     Abstract available


  10. HINZ S, Hendricks A, Wittig A, Schafmayer C, et al
    Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study.
    BMC Cancer. 2017;17:53.
    PubMed     Text format     Abstract available


  11. QIU P, Wang S, Liu M, Ma H, et al
    Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells.
    BMC Cancer. 2017;17:55.
    PubMed     Text format     Abstract available


  12. PALSHOF JA, Hogdall EV, Poulsen TS, Linnemann D, et al
    Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
    BMC Cancer. 2017;17:48.
    PubMed     Text format     Abstract available


  13. NAKAYAMA I, Shinozaki E, Matsushima T, Wakatsuki T, et al
    Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    BMC Cancer. 2017;17:38.
    PubMed     Text format     Abstract available


  14. KURODA K, Fukuda T, Krstic-Demonacos M, Demonacos C, et al
    miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway.
    BMC Cancer. 2017;17:33.
    PubMed     Text format     Abstract available


  15. NAING C, Aung K, Lai PK, Mak JW, et al
    Association between telomere length and the risk of colorectal cancer: a meta-analysis of observational studies.
    BMC Cancer. 2017;17:24.
    PubMed     Text format     Abstract available


  16. AL-KHAYAL K, Alafeefy A, Vaali-Mohammed MA, Mahmood A, et al
    Novel derivative of aminobenzenesulfonamide (3c) induces apoptosis in colorectal cancer cells through ROS generation and inhibits cell migration.
    BMC Cancer. 2017;17:4.
    PubMed     Text format     Abstract available


    December 2016
  17. MODARAI SR, Opdenaker LM, Viswanathan V, Fields JZ, et al
    Somatostatin signaling via SSTR1 contributes to the quiescence of colon cancer stem cells.
    BMC Cancer. 2016;16:941.
    PubMed     Text format     Abstract available


    November 2016
  18. KLOSE J, Eissele J, Volz C, Schmitt S, et al
    Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/beta-catenin signaling in CD133+ human colorectal cancer cells.
    BMC Cancer. 2016;16:896.
    PubMed     Text format     Abstract available


  19. PAWLAK A, Ziolo E, Fiedorowicz A, Fidyt K, et al
    Long-lasting reduction in clonogenic potential of colorectal cancer cells by sequential treatments with 5-azanucleosides and topoisomerase inhibitors.
    BMC Cancer. 2016;16:893.
    PubMed     Text format     Abstract available


  20. MEERSON A, Yehuda H
    Leptin and insulin up-regulate miR-4443 to suppress NCOA1 and TRAF4, and decrease the invasiveness of human colon cancer cells.
    BMC Cancer. 2016;16:882.
    PubMed     Text format     Abstract available


  21. REFAAT B, El-Shemi AG, Mohamed AM, Kensara OA, et al
    Activins and their related proteins in colon carcinogenesis: insights from early and advanced azoxymethane rat models of colon cancer.
    BMC Cancer. 2016;16:879.
    PubMed     Text format     Abstract available


  22. ZHOU L, Yu L, Zhu B, Wu S, et al
    Metastasis-associated in colon cancer-1 and aldehyde dehydrogenase 1 are metastatic and prognostic biomarker for non-small cell lung cancer.
    BMC Cancer. 2016;16:876.
    PubMed     Text format     Abstract available


    October 2016
  23. BOLEIJ A, Tack V, Taylor A, Kafatos G, et al
    RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.
    BMC Cancer. 2016;16:825.
    PubMed     Text format     Abstract available


  24. XU C, Zhou D, Pan F, Liu Y, et al
    A novel variant on chromosome 6p21.1 is associated with the risk of developing colorectal cancer: a two-stage case-control study in Han Chinese.
    BMC Cancer. 2016;16:807.
    PubMed     Text format     Abstract available


  25. DING C, Li L, Yang T, Fan X, et al
    Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    BMC Cancer. 2016;16:791.
    PubMed     Text format     Abstract available


  26. FORREST CM, McNair K, Vincenten MC, Darlington LG, et al
    Selective depletion of tumour suppressors Deleted in Colorectal Cancer (DCC) and neogenin by environmental and endogenous serine proteases: linking diet and cancer.
    BMC Cancer. 2016;16:772.
    PubMed     Text format     Abstract available


  27. MYERS RE, Wolf T, Shwae P, Hegarty S, et al
    A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients.
    BMC Cancer. 2016;16:766.
    PubMed     Text format     Abstract available


    January 2016
  28. DUTTA D, Chakraborty B, Sarkar A, Chowdhury C, et al
    A potent betulinic acid analogue ascertains an antagonistic mechanism between autophagy and proteasomal degradation pathway in HT-29 cells.
    BMC Cancer. 2016;16:23.
    PubMed     Text format     Abstract available


  29. JIANG Y, Li W, He X, Zhang H, et al
    Lgr5 expression is a valuable prognostic factor for colorectal cancer: evidence from a meta-analysis.
    BMC Cancer. 2016;16:12.
    PubMed     Text format     Abstract available


  30. KIM HS, Heo JS, Lee J, Lee JY, et al
    The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis.
    BMC Cancer. 2016;16:120.
    PubMed     Text format     Abstract available


  31. SAVIO AJ, Daftary D, Dicks E, Buchanan DD, et al
    Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients.
    BMC Cancer. 2016;16:113.
    PubMed     Text format     Abstract available


  32. RAZENBERG LG, van Gestel YR, de Hingh IH, Loosveld OJ, et al
    Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice.
    BMC Cancer. 2016;16:110.
    PubMed     Text format     Abstract available


  33. WEIXLER B, Warschkow R, Guller U, Zettl A, et al
    Isolated tumor cells in stage I & II colon cancer patients are associated with significantly worse disease-free and overall survival.
    BMC Cancer. 2016;16:106.
    PubMed     Text format     Abstract available


  34. SABER MM, Galal MA, Ain-Shoka AA, Shouman SA, et al
    Combination of metformin and 5-aminosalicylic acid cooperates to decrease proliferation and induce apoptosis in colorectal cancer cell lines.
    BMC Cancer. 2016;16:126.
    PubMed     Text format     Abstract available


  35. KARAHALIOS A, Simpson JA, Baglietto L, MacInnis RJ, et al
    Change in weight and waist circumference and risk of colorectal cancer: results from the Melbourne Collaborative Cohort Study.
    BMC Cancer. 2016;16:157.
    PubMed     Text format     Abstract available


  36. WARD ST, Weston CJ, Shepherd EL, Hejmadi R, et al
    Evaluation of serum and tissue levels of VAP-1 in colorectal cancer.
    BMC Cancer. 2016;16:154.
    PubMed     Text format     Abstract available


  37. SAKELLARIOU S, Fragkou P, Levidou G, Gargalionis AN, et al
    Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis.
    BMC Cancer. 2016;16:174.
    PubMed     Text format     Abstract available


  38. WEIXLER B, Warschkow R, Ramser M, Droeser R, et al
    Urgent surgery after emergency presentation for colorectal cancer has no impact on overall and disease-free survival: a propensity score analysis.
    BMC Cancer. 2016;16:208.
    PubMed     Text format     Abstract available


  39. LI G, Wang Z, Xu J, Wu H, et al
    The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis.
    BMC Cancer. 2016;16:249.
    PubMed     Text format     Abstract available


  40. CHRISTENSEN TD, Spindler KL, Palshof JA, Nielsen DL, et al
    Systematic review: brain metastases from colorectal cancer-Incidence and patient characteristics.
    BMC Cancer. 2016;16:260.
    PubMed     Text format     Abstract available


  41. LIU Z, Zhang K, Du XL
    Risks of developing breast and colorectal cancer in association with incomes and geographic locations in Texas: a retrospective cohort study.
    BMC Cancer. 2016;16:294.
    PubMed     Text format     Abstract available


  42. DIAO D, Wang L, Wan J, Chen Z, et al
    MEK5 overexpression is associated with the occurrence and development of colorectal cancer.
    BMC Cancer. 2016;16:302.
    PubMed     Text format     Abstract available


  43. CHEN KH, Shao YY, Chen HM, Lin YL, et al
    Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.
    BMC Cancer. 2016;16:327.
    PubMed     Text format     Abstract available


  44. SEGELOV E, Waring P, Desai J, Wilson K, et al
    ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
    BMC Cancer. 2016;16:339.
    PubMed     Text format     Abstract available


  45. KURAMOCHI H, Nakamura A, Nakajima G, Kaneko Y, et al
    PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational study.
    BMC Cancer. 2016;16:366.
    PubMed     Text format     Abstract available


  46. PARK WC, Kim HR, Kang DB, Ryu JS, et al
    Comparative expression patterns and diagnostic efficacies of SR splicing factors and HNRNPA1 in gastric and colorectal cancer.
    BMC Cancer. 2016;16:358.
    PubMed     Text format     Abstract available


  47. GOVINDARAJAN R, Posey J, Chao CY, Lu R, et al
    A comparison of 12-gene colon cancer assay gene expression in African American and Caucasian patients with stage II colon cancer.
    BMC Cancer. 2016;16:368.
    PubMed     Text format     Abstract available


  48. QUINTANA JM, Gonzalez N, Anton-Ladislao A, Redondo M, et al
    Colorectal cancer health services research study protocol: the CCR-CARESS observational prospective cohort project.
    BMC Cancer. 2016;16:435.
    PubMed     Text format     Abstract available


  49. ADENIS A, de la Fouchardiere C, Paule B, Burtin P, et al
    Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program.
    BMC Cancer. 2016;16:412.
    PubMed     Text format     Abstract available


  50. ALLARY C, Bourmaud A, Tinquaut F, Oriol M, et al
    ColoNav: patient navigation for colorectal cancer screening in deprived areas - Study protocol.
    BMC Cancer. 2016;16:416.
    PubMed     Text format     Abstract available


  51. BELLAMKONDA K, Chandrashekar NK, Osman J, Selvanesan BC, et al
    The eicosanoids leukotriene D4 and prostaglandin E2 promote the tumorigenicity of colon cancer-initiating cells in a xenograft mouse model.
    BMC Cancer. 2016;16:425.
    PubMed     Text format     Abstract available


  52. LAAKE I, Larsen IK, Selmer R, Thune I, et al
    Pre-diagnostic body mass index and weight change in relation to colorectal cancer survival among incident cases from a population-based cohort study.
    BMC Cancer. 2016;16:402.
    PubMed     Text format     Abstract available


  53. WANG X, Chen J, Wang J, Yu F, et al
    Metalloproteases meprin-a (MEP1A) is a prognostic biomarker and promotes proliferation and invasion of colorectal cancer.
    BMC Cancer. 2016;16:383.
    PubMed     Text format     Abstract available


  54. PETRELLI F, Barni S, Bertocchi P, Zaniboni A, et al
    TAS-102, the first "cardio-gentle" fluoropyrimidine in the colorectal cancer landscape?
    BMC Cancer. 2016;16:386.
    PubMed     Text format     Abstract available


  55. LI WM, Hu TT, Zhou LL, Feng YM, et al
    Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method.
    BMC Cancer. 2016;16:454.
    PubMed     Text format     Abstract available


  56. KLUPP F, Neumann L, Kahlert C, Diers J, et al
    Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients.
    BMC Cancer. 2016;16:494.
    PubMed     Text format     Abstract available


  57. KASI PM, Kotani D, Cecchini M, Shitara K, et al
    Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
    BMC Cancer. 2016;16:467.
    PubMed     Text format     Abstract available


  58. CHU QD, Zhou M, Medeiros KL, Peddi P, et al
    Poor survival in stage IIB/C (T4N0) compared to stage IIIA (T1-2 N1, T1N2a) colon cancer persists even after adjusting for adequate lymph nodes retrieved and receipt of adjuvant chemotherapy.
    BMC Cancer. 2016;16:460.
    PubMed     Text format     Abstract available


  59. LUNDBERG IV, Edin S, Eklof V, Oberg A, et al
    SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
    BMC Cancer. 2016;16:471.
    PubMed     Text format     Abstract available


  60. WARSCHKOW R, Sulz MC, Marti L, Tarantino I, et al
    Better survival in right-sided versus left-sided stage I - III colon cancer patients.
    BMC Cancer. 2016;16:554.
    PubMed     Text format     Abstract available


  61. MARTINS SF, Amorim R, Viana-Pereira M, Pinheiro C, et al
    Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis.
    BMC Cancer. 2016;16:535.
    PubMed     Text format     Abstract available


  62. ADENIS A, de la Fouchardiere C, Paule B, Burtin P, et al
    Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
    BMC Cancer. 2016;16:518.
    PubMed     Text format    


  63. FREEMAN K, Saunders MP, Uthman OA, Taylor-Phillips S, et al
    Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review.
    BMC Cancer. 2016;16:523.
    PubMed     Text format     Abstract available


  64. IKEYA T, Maeda K, Nagahara H, Shibutani M, et al
    The combined expression of Semaphorin4D and PlexinB1 predicts disease recurrence in colorectal cancer.
    BMC Cancer. 2016;16:525.
    PubMed     Text format     Abstract available


  65. DAMM R, Seidensticker R, Ulrich G, Breier L, et al
    Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system.
    BMC Cancer. 2016;16:509.
    PubMed     Text format     Abstract available


  66. MACK E, Stabla K, Riera-Knorrenschild J, Moll R, et al
    A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing.
    BMC Cancer. 2016;16:585.
    PubMed     Text format     Abstract available


  67. JAGADISH N, Parashar D, Gupta N, Agarwal S, et al
    Heat shock protein 70-2 (HSP70-2) is a novel therapeutic target for colorectal cancer and is associated with tumor growth.
    BMC Cancer. 2016;16:561.
    PubMed     Text format     Abstract available


  68. ANTUNES L, Mendonca D, Bento MJ, Rachet B, et al
    No inequalities in survival from colorectal cancer by education and socioeconomic deprivation - a population-based study in the North Region of Portugal, 2000-2002.
    BMC Cancer. 2016;16:608.
    PubMed     Text format     Abstract available


  69. LI C, Zhao L, Chen Y, He T, et al
    MicroRNA-21 promotes proliferation, migration, and invasion of colorectal cancer, and tumor growth associated with down-regulation of sec23a expression.
    BMC Cancer. 2016;16:605.
    PubMed     Text format     Abstract available


  70. BOTREL TE, Clark LG, Paladini L, Clark OA, et al
    Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis.
    BMC Cancer. 2016;16:677.
    PubMed     Text format     Abstract available


  71. ZHANG ZY, Luo QF, Yin XW, Dai ZL, et al
    Nomograms to predict survival after colorectal cancer resection without preoperative therapy.
    BMC Cancer. 2016;16:658.
    PubMed     Text format     Abstract available


  72. PITA-FERNANDEZ S, Gonzalez-Saez L, Lopez-Calvino B, Seoane-Pillado T, et al
    Effect of diagnostic delay on survival in patients with colorectal cancer: a retrospective cohort study.
    BMC Cancer. 2016;16:664.
    PubMed     Text format     Abstract available


  73. LI C, Zhou L, He J, Fang XQ, et al
    Increased long noncoding RNA SNHG20 predicts poor prognosis in colorectal cancer.
    BMC Cancer. 2016;16:655.
    PubMed     Text format     Abstract available


  74. PADHAN N, Nordling TE, Sundstrom M, Akerud P, et al
    High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer.
    BMC Cancer. 2016;16:683.
    PubMed     Text format     Abstract available


  75. PARK JS, Huh JW, Park YA, Cho YB, et al
    Clinically suspected T4 colorectal cancer may be resected using a laparoscopic approach.
    BMC Cancer. 2016;16:714.
    PubMed     Text format     Abstract available


  76. AKINYEMIJU T, Meng Q, Vin-Raviv N
    Race/ethnicity and socio-economic differences in colorectal cancer surgery outcomes: analysis of the nationwide inpatient sample.
    BMC Cancer. 2016;16:715.
    PubMed     Text format     Abstract available


  77. LEE KS, Kwak Y, Nam KH, Kim DW, et al
    Favorable prognosis in colorectal cancer patients with co-expression of c-MYC and ss-catenin.
    BMC Cancer. 2016;16:730.
    PubMed     Text format     Abstract available


    January 2015
  78. TOPS B, Normanno N, Kurth H, Amato E, et al
    Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium.
    BMC Cancer. 2015;15:26.
    PubMed     Text format     Abstract available


  79. DENG Y, Cai Y, Huang Y, Yang Z, et al
    High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment.
    BMC Cancer. 2015;15:833.
    PubMed     Text format     Abstract available


  80. YOUNG GM, Radhakrishnan VM, Centuori SM, Gomes CJ, et al
    Comparative analysis of 14-3-3 isoform expression and epigenetic alterations in colorectal cancer.
    BMC Cancer. 2015;15:826.
    PubMed     Text format     Abstract available


  81. ORNTOFT MB, Nielsen HJ, Orntoft TF, Andersen CL, et al
    Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study.
    BMC Cancer. 2015;15:819.
    PubMed     Text format     Abstract available


  82. FORNARO L, Faviana P, De Gregorio V, Vivaldi C, et al
    Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.
    BMC Cancer. 2015;15:874.
    PubMed     Text format     Abstract available


  83. CUTLER MJ, Lowthers EL, Richard CL, Hajducek DM, et al
    Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26.
    BMC Cancer. 2015;15:882.
    PubMed     Text format     Abstract available


  84. XU S, Chen M, Chen W, Hui J, et al
    Chemopreventive effect of chalcone derivative, L2H17, in colon cancer development.
    BMC Cancer. 2015;15:870.
    PubMed     Text format     Abstract available


  85. YAMANO T, Semba S, Noda M, Yoshimura M, et al
    Prognostic significance of classified extramural tumor deposits and extracapsular lymph node invasion in T3-4 colorectal cancer: a retrospective single-center study.
    BMC Cancer. 2015;15:859.
    PubMed     Text format     Abstract available


  86. GU XD, Cai YT, Zhou YM, Li ZY, et al
    Prognostic factors and multidisciplinary treatment modalities for brain metastases from colorectal cancer: analysis of 93 patients.
    BMC Cancer. 2015;15:902.
    PubMed     Text format     Abstract available


  87. KOEHLER BC, Jassowicz A, Scherr AL, Lorenz S, et al
    Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling.
    BMC Cancer. 2015;15:919.
    PubMed     Text format     Abstract available


  88. HAN C, Shin A, Lee J, Lee J, et al
    Dietary calcium intake and the risk of colorectal cancer: a case control study.
    BMC Cancer. 2015;15:966.
    PubMed     Text format     Abstract available


  89. JIANG Y, Li W, He X, Zhang H, et al
    Lgr5 expression is a valuable prognostic factor for colorectal cancer: evidence from a meta-analysis.
    BMC Cancer. 2015;15:948.
    PubMed     Text format     Abstract available


  90. YANG S, Li W, Sun H, Wu B, et al
    Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo.
    BMC Cancer. 2015;15:969.
    PubMed     Text format     Abstract available


  91. LI X, Pathi SS, Safe S
    Sulindac sulfide inhibits colon cancer cell growth and downregulates specificity protein transcription factors.
    BMC Cancer. 2015;15:974.
    PubMed     Text format     Abstract available


  92. HOLMER R, Watzig GH, Tiwari S, Rose-John S, et al
    Interleukin-6 trans-signaling increases the expression of carcinoembryonic antigen-related cell adhesion molecules 5 and 6 in colorectal cancer cells.
    BMC Cancer. 2015;15:975.
    PubMed     Text format     Abstract available


  93. ASHKTORAB H, Ogundipe T, Brim H, Shahnazi A, et al
    Lymph nodes' evaluation in relation to colorectal cancer staging among African Americans.
    BMC Cancer. 2015;15:976.
    PubMed     Text format     Abstract available


  94. BAUER A, Vordermark D, Seufferlein T, Schmoll HJ, et al
    Trans-sectoral care in patients with colorectal cancer: Protocol of the randomized controlled multi-center trial Supportive Cancer Care Networkers (SCAN).
    BMC Cancer. 2015;15:997.
    PubMed     Text format     Abstract available


  95. SHI D, Cai G, Peng J, Li D, et al
    The preoperative SUVmax for (18)F-FDG uptake predicts survival in patients with colorectal cancer.
    BMC Cancer. 2015;15:991.
    PubMed     Text format     Abstract available


  96. XU X, Chen R, Li Z, Huang N, et al
    MicroRNA-490-3p inhibits colorectal cancer metastasis by targeting TGFbetaR1.
    BMC Cancer. 2015;15:1023.
    PubMed     Text format     Abstract available


  97. ALEXANDRINO H, Oliveira D, Cipriano MA, Ferreira L, et al
    Oxaliplatin toxicity presenting as a liver nodule - case report.
    BMC Cancer. 2015;15:247.
    PubMed     Text format     Abstract available


  98. GRASSO S, Martinez-Lacaci I, Barbera VM, Castillejo A, et al
    HGUE-C-1 is an atypical and novel colon carcinoma cell line.
    BMC Cancer. 2015;15:240.
    PubMed     Text format     Abstract available


  99. ZHENG X, Zhou J, Zhang B, Zhang J, et al
    Critical evaluation of Cbx7 downregulation in primary colon carcinomas and its clinical significance in Chinese patients.
    BMC Cancer. 2015;15:145.
    PubMed     Text format     Abstract available


  100. HE J, Shin H, Wei X, Kadegowda AK, et al
    NPC1L1 knockout protects against colitis-associated tumorigenesis in mice.
    BMC Cancer. 2015;15:189.
    PubMed     Text format     Abstract available


  101. COTTE E, Villeneuve L, Passot G, Boschetti G, et al
    GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study.
    BMC Cancer. 2015;15:47.
    PubMed     Text format     Abstract available


  102. SALAZAR R, Capdevila J, Laquente B, Manzano JL, et al
    A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.
    BMC Cancer. 2015;15:60.
    PubMed     Text format     Abstract available


  103. GARCIA M, Martinez-Villacampa M, Santos C, Navarro V, et al
    Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer.
    BMC Cancer. 2015;15:59.
    PubMed     Text format     Abstract available


  104. YANG GZ, Hu L, Cai J, Chen HY, et al
    Prognostic value of carbonic anhydrase VII expression in colorectal carcinoma.
    BMC Cancer. 2015;15:209.
    PubMed     Text format     Abstract available


  105. JAYASINGHE C, Simiantonaki N, Kirkpatrick CJ
    Histopathological features predict metastatic potential in locally advanced colon carcinomas.
    BMC Cancer. 2015;15:14.
    PubMed     Text format     Abstract available


  106. LI L, Chen Z, Wang X, Li H, et al
    Detection of morphologic alterations in rectal carcinoma following preoperative radiochemotherapy based on multiphoton microscopy imaging.
    BMC Cancer. 2015;15:142.
    PubMed     Text format     Abstract available


  107. HENRY CJ, Sedjo RL, Rozhok A, Salstrom J, et al
    Lack of significant association between serum inflammatory cytokine profiles and the presence of colorectal adenoma.
    BMC Cancer. 2015;15:123.
    PubMed     Text format     Abstract available


  108. LI W, Qiu T, Zhi W, Shi S, et al
    Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
    BMC Cancer. 2015;15:340.
    PubMed     Text format     Abstract available


  109. SCHOELLHAMMER HF, Goldner B, Merchant SJ, Kessler J, et al
    Colorectal liver metastases: making the unresectable resectable using irreversible electroporation for microscopic positive margins - a case report.
    BMC Cancer. 2015;15:271.
    PubMed     Text format     Abstract available


  110. JONES M, Hruby G, Stanwell P, Gallagher S, et al
    Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy.
    BMC Cancer. 2015;15:281.
    PubMed     Text format     Abstract available


  111. ZHOU HM, Fang YY, Weinberger PM, Ding LL, et al
    Transgelin increases metastatic potential of colorectal cancer cells in vivo and alters expression of genes involved in cell motility.
    BMC Cancer. 2016;16:55.
    PubMed     Text format     Abstract available


  112. AYEZ N, van der Stok EP, de Wilt H, Radema SA, et al
    Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial.
    BMC Cancer. 2015;15:180.
    PubMed     Text format     Abstract available


  113. AVALLONE A, Piccirillo MC, Aloj L, Nasti G, et al
    A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
    BMC Cancer. 2016;16:69.
    PubMed     Text format     Abstract available


  114. CHAMBERS JA, Callander AS, Grangeret R, O'Carroll RE, et al
    Attitudes towards the Faecal Occult Blood Test (FOBT) versus the Faecal Immunochemical Test (FIT) for colorectal cancer screening: perceived ease of completion and disgust.
    BMC Cancer. 2016;16:96.
    PubMed     Text format     Abstract available


  115. SHARMIN M, Bravo HC, Hannenhalli S
    Distinct genomic and epigenomic features demarcate hypomethylated blocks in colon cancer.
    BMC Cancer. 2016;16:88.
    PubMed     Text format     Abstract available


  116. TARPGAARD LS, Qvortrup C, Nygard SB, Nielsen SL, et al
    A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.
    BMC Cancer. 2016;16:91.
    PubMed     Text format     Abstract available


  117. STEIN A, Quidde J, Schroder JK, Gohler T, et al
    Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study.
    BMC Cancer. 2016;16:82.
    PubMed     Text format     Abstract available


  118. CAMPTON DE, Ramirez AB, Nordberg JJ, Drovetto N, et al
    High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining.
    BMC Cancer. 2015;15:360.
    PubMed     Text format     Abstract available


  119. CARDOSO AP, Pinto ML, Pinto AT, Pinto MT, et al
    Matrix metalloproteases as maestros for the dual role of LPS- and IL-10-stimulated macrophages in cancer cell behaviour.
    BMC Cancer. 2015;15:456.
    PubMed     Text format     Abstract available


  120. MENG F, Bhupathi D, Sun JD, Liu Q, et al
    Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
    BMC Cancer. 2015;15:422.
    PubMed     Text format     Abstract available


  121. LIU L, Yu H, Huang X, Tan H, et al
    A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity.
    BMC Cancer. 2015;15:170.
    PubMed     Text format     Abstract available


  122. KIM JH, Park JM, Roh YJ, Kim IW, et al
    Enhanced efficacy of photodynamic therapy by inhibiting ABCG2 in colon cancers.
    BMC Cancer. 2015;15:504.
    PubMed     Text format     Abstract available


  123. MCCAHON D, Daley AJ, Jones J, Haslop R, et al
    Enhancing adherence in trials promoting change in diet and physical activity in individuals with a diagnosis of colorectal adenoma; a systematic review of behavioural intervention approaches.
    BMC Cancer. 2015;15:505.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: